华泰金融(HK)：给予金斯瑞生物科技(01548.HK)“买入”评级 目标价23.95港元
来源：
同花顺金融研究中心
华泰金融(HK)10月20日发布公告。We maintain our full-year sales forecast for CARVYKTI of over USD900mn for 2024, and project the company’s 2024/2025/2026 attributable net profit at USD-118/+146/+596mn, corresponding to EPS of USD-0.06/+0.07/+0.28, given the ongoing sales ramp-up of CARVYKTI and solid performance in life sciences. Our SOTP-derived target market cap is HKD51.0bn (HKD26.4/24.5bn for non-cell/cell therapy), with our target price of HKD23.95 (previous: HKD26.04). Maintain BUY.
0人
